hs-CRP/HDL-C

1. hs-CRP/HDL-C improves cardiometabolic multimorbidity prediction performance in humans (AUC 0.615 versus 0.604 for hs-CRP and 0.411 for HDL-C).

   “the area under the curve for hs-CRP/HDL-C in predicting CMM was 0.615, superior to prediction using hs-CRP(0.604) or HDL-C(0.411) alone.”

   HumansCompared with hs-CRP or HDL-C alone9.8(8.7,10.5) yearsn = 2,892

   Effect of the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio on cardiometabolic multimorbidity in people aged 60 years and older

   Chinese Journal of Geriatric Heart Brain and Vessel Diseases·15 Sep 2026

1. hs-CRP/HDL-C is associated with cardiometabolic multimorbidity in humans (OR 1.233, 95% CI 1.033–1.390).

   “the risks of developing CMM were significantly higher in the Q3 and Q4 groups (OR=1.233,95%CI:1.033~1.390,P<0.05;OR=1.241,95%CI:1.108~1.473, P<0.01)”

   Humanshs-CRP/HDL-C Q3 (23.26~61.93) versus Q1 (<11.02); multivariable-adjusted analysis9.8(8.7,10.5) yearsn = 2,892

   Effect of the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio on cardiometabolic multimorbidity in people aged 60 years and older

   Chinese Journal of Geriatric Heart Brain and Vessel Diseases·15 Sep 2026

More on Cardiometabolic multimorbidity